News

Under the pact, both the companies are expected to develop drugs for the treatment of autoimmune diseases like psoriasis, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Further,

The multi-centre, randomised, double-blind proof-of-concept clinical trial will compare the use of a catheter irrigation solution containing NVC-422 versus the use of a saline irrigation, the commonly used

IPI-926 is a novel, oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway. The activation of the Hedgehog pathway is believed to be involved in

The termination will be effective in May 2011. After the termination, Targacept is expected to have full rights to its programs subject to the alliance, including compounds discovered

Transcend plans for acquiring DTS by the merger of DTS and a subsidiary of Transcend. The acquisition is expected to be of $7.9m in cash, plus an earn-out

Banzel has been approved for the adjunctive treatment of seizures linked with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults. Eisai claims that its Banzel

Under the pact, both the companies will focus on developing RFID technologies for various areas where secure & reliable identification is a key requirement. Steria and Neology claim

OraSure Technologies’ Intercept Drug Testing System is the FDA-cleared in vitro diagnostic laboratory-based oral fluid testing system used for detecting commonly abused drugs such as marijuana, cocaine, opiates,

Reportedly, the Phase 3 Telatinib trial will compare Telatinib in conjunction with a standard regimen of chemotherapy versus chemotherapy alone in advanced stomach cancer patients. ACT Biotech said